A multicenter, double-blind, randomized, parallel group, positive-controlled trial comparing the efficacy and safety of levetiracetam (1000 to 3000 mg/day oral b.i.d. [twice daily] to carabamazepine (400 to 1200 mg/day oral b.i.d.), used as monotherapy for up to a maximum of 121 weeks in subjects (greater than or equal to 16 years) newly or recently diagnosed as suffering from epilepsy, and experiencing partial or generalized tonic-clonic seizures.

Trial Profile

A multicenter, double-blind, randomized, parallel group, positive-controlled trial comparing the efficacy and safety of levetiracetam (1000 to 3000 mg/day oral b.i.d. [twice daily] to carabamazepine (400 to 1200 mg/day oral b.i.d.), used as monotherapy for up to a maximum of 121 weeks in subjects (greater than or equal to 16 years) newly or recently diagnosed as suffering from epilepsy, and experiencing partial or generalized tonic-clonic seizures.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2014

At a glance

  • Drugs Levetiracetam (Primary) ; Carbamazepine
  • Indications Partial epilepsies; Tonic-clonic epilepsy
  • Focus Registrational; Therapeutic Use
  • Sponsors UCB Pharma Inc
  • Most Recent Events

    • 10 Oct 2006 Status change
    • 13 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top